- References (2)
- Inventor Info
|Antigen/Gene or Protein Targets||SARS CoV ORF7a (also known as U122)|
Monoclonal antibody used to study the role of ORF7a within SARS coronavirus.
Background and Research Application
A novel coronavirus (termed as SARS-CoV) has been identified as the etiological agent of severe acute respiratory syndrome (SARS). The SARS-CoV genome encodes the essential CoV replication and structural proteins. In addition, the genome encodes eight 8 putative accessory proteins (i.e. ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b and 9b) that do not show significant homology to viral proteins of known coronaviruses, i.e. they are unique to SARS-CoV. It is known to infect humans, bats and various other mammals.
ORF7a, also known as U122, consists of 122 amino acids and is localized mainly in ER-Golgi intermediate compartment, where coronaviruses are known to assemble and bud. ORF7a can also be incorporated into the virion. The over-expression of ORF7a induces apoptosis and block cell cycle progression at G0/G1 phase. This is via interfering with pro-survival proteins such as Bcl-XL, Bcl-w, Mcl-1, and A1.
|Immunogen||GST-7a (16-111 amino acids)|
Immunogen UniProt ID
|Molecular Weight (kDa)||14|
Purified using multi-step affinity chromatography with protein A.
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.
Points of Interest
Overexpression of Bcl-XL blocks the induction of apoptosis by ORF7a, indicating that ORF7a may be acting at the level of or upstream from the Bcl-2 family.
One study showed that the over-expression of ORF7a inhibited cellular protein synthesis and induced the phosphorylation and activation of p38 mitogen activated protein kinase (MAPK).
1mg/ml as standard
|Research Area||Cell Signaling & Signal Transduction, Neurobiology|
There are 2 reference entries for this reagent.View All References
No inventors are currently linked to this reagent.
Add an inventor
Add an inventor